collaborations

Targeting cancer through CD40 agonists -A promising future

Cluster of differentiation 40 or CD40 is a co-stimulatory protein found on the antigen presenting cells of the immune system. Agonistic CD40 molecules which include monoclonal antibodies (mAb) offe...


Business Cocktail

Takeda and Portal Instruments partner to bring about needle-free form of drug delivery Takeda Pharmaceutical and Portal Instruments have partnered with a deal worth $100 million to develop a needle...


Novo petitions FDA;J&J invests; Xarelto’s trial; Roche’s Tecentriq

Novo petitions FDA to require copies of Victoza to conduct clinical trials With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expir...


Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for t...

Thrombolytic Sciences announced completion of Phase I TS01 trial A clinical stage vascular health and biotech company, Thrombolytic Science, LLC (TSI), announced the completion of its Phase I trial...


Business cocktail

Bayer and Berkeley Lights embark on a project to automate drug discovery Pharmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discov...


Personalized Medicine
Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads...

Loom of Patent Expiry leads Bristol-Myers Squibb to nix 58 marketing jobs Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs—and, as a result, 58 workers will ...


Personalized Medicine
Merck got attack; Stada’s €5.32B; Private equity fund buys; Lonza on $5.5B deal

Merck targeted in global ransomware attack Merck & Co. was among those affected by a massive ransomware attack Tuesday that infiltrated the computer systems of companies around the world as wel...


Cancer, diabetes and eczema on list; AbbVie’s Humira; Teva weighs $2B; Fresenius in buyout ...

Cancer, diabetes and eczema star in 2017 top-launch list Launch prognostications are getting more attention than ever as they come out with “Drugs to Watch” list, and the highlights of different dr...


Therapeutics
Valeant’s asset-sale; Sanofi coughs up $19.8M; Sanofi’s Genzyme; India’s Alkem;...

Valeant's asset-sale woes continue as Stada, Mundipharma lowball iNova bids Embattled Valeant has promised its investors $8 billion in asset sales—but as the company’s latest deal struggles continu...


Mylan closing Illinois plant; Insys spends $24M; Roche’s Ocrevus; Greece’s corruption prose...

Mylan closing Illinois plant, cutting 90 jobs as part of slim-down after Meda buyout Mylan has been in the midst of cutting about 3,500 jobs to decrease costs and refocus after its $7 billion buyou...


Editor's Pick
Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

Global Top Players in Intraocular Lens (IOL) Market

 An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...

Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape

Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...

LAG 3: A Promising Next Generation Cancer Immunotherapy

Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.